ZNTL Stock — Zentalis Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$3.11

Market cap

$294.4M

Cash

$249.7M

Enterprise value

$44.7M

Balance sheet

Cash	$249.7M
Debt	$0.0M
Net cash	$249.7M
Enterprise value	$44.7M
Basic shares	71.7M shares
Fully diluted shares	90.6M shares
Fully diluted market cap	$281.7M
Cash per share	$3.48

Cash figures as of 2026-08-17. Database snapshot: 2026-09-21.

Price history

Loading ZNTL daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	azenosertib	Phase 2	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	H1 2027
Jul 12 - Aug 23	Azenosertib	Phase 3	Ovarian Cancer	—
Aug 11 - Sep 22	Azenosertib	Phase 1	Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Azenosertib

Phase 3 · Active Modality: small molecule (WEE1 inhibitor)

Aliases ZN-c3

Target WEE1

Partnerships Recurium IP: exclusive worldwide license ($7.0M milestone paid in Q2 2026 upon commencement of ASPENOVA Phase 3; development/regulatory milestones up to $44.5M per product for first two indications; mid- to high-single-digit royalties)

Indications

Cyclin E1-positive platinum-resistant ovarian cancer (PROC) (Phase 2)
Solid tumors (in combination with chemotherapy regimens) (Phase 1)

Status note Only product candidate in clinical development. DENALI Part 2 could support accelerated approval; ASPENOVA Phase 3 confirmatory monotherapy commenced (Q2 2026); MUIR Phase 1b evaluating combination with chemotherapy regimens. FDA approval of a companion diagnostic is expected to be required for the lead indication.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Investigator's choice of Chemotherapy
Lead indication	Ovarian Cancer
Lead phase	Phase 3
Active trials	3
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07546500	Phase 3	Recruiting	Sponsor	ZNTL	—	Ovarian Cancer	—
NCT05128825	Phase 2	Recruiting	Sponsor	ZNTL	—	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	H1 2027
NCT04516447	Phase 1	Recruiting	Sponsor	ZNTL	—	Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer	—
NCT06015659	Phase 2	Active, not recruiting	Collaborator	Brandon Huffman, MD	—	Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	1,390,576	+1,390,576	0.13%	2026-08-14
ADAR1 Capital Management	652,750	+508,114	0.15%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ZNTL — Zentalis Pharmaceuticals Inc.